Momentum Stock Watch: Daré Bioscience, Inc. (DARE)

Company Profile:

Daré Bioscience, Inc., a clinical-stage biopharmaceutical company, focuses on developing and marketing women’s reproductive health products in the United States. The company intends to develop therapies in the areas of contraception, vaginal health, sexual health, and fertility. Its product candidates include Ovaprene, a non-hormonal monthly contraceptive; and SST-6007, a topical sildenafil cream for female sexual arousal disorder. The company has license and collaboration agreement with Strategic Science and Technologies-D, LLC and Strategic Science Technologies, LLC to develop and commercialize indications for women related to female sexual dysfunction and/or female reproductive health. The company was incorporated in 2005 and is headquartered in La Jolla, California.

Recent News:

On July 16, 2018, the company announced that it has entered into an asset transfer agreement with Hydra Biosciences, Inc. for the transfer of all of Hydra’s interest in certain intellectual property relating to Hydra’s CatSper ion channel target portfolio.

John Fair, Chief Business Officer, will present at the H.C. Wainwright 20th Annual Global Investment Conference on Thursday, September 6, 2018 at 12:05 p.m. Eastern Time. In addition to presenting a corporate overview, Mr. Fair will provide details on the Company’s portfolio programs.

 

Fundamental Analysis:

Ninestocks analyzes several different financial aspects: Growth, Profitability, solvency and efficiency.

Growth – Measures the growth of both the company’s income statement and cash flow.

@@@@@

Profitability – Measures the historical price movement of the stock.

@@@@@

Solvency – Measures the solvency of the company based on several ratios.

@@@@@

Efficiency – Measures the strength and historic growth of a company’s return on invested capital.

@@@@@

Conclusion:

DARE’s strengths can be seen in its strong growth compared with its peers. Technical indicators signal the bullish signs, as there is a bullish crossover in MACD and Stochastic oscillator, RSI stands at 50.15 with positive bias. We rate Daré Bioscience, Inc. (DARE) a STRONG BUY.

About the Author

has written 10339 stories on this site.

Copyright © 2012 Nine Stocks